Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04155 (
pS2
)
1,234
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Activin is a member of the transforming growth factor beta superfamily that regulates mammary cell function during development, lactation, and in cancer. Activin slows the growth of breast cancer cells by inducing G(0)/G(1) cell cycle arrest. Estrogen is a steroid hormone that stimulates the proliferation of mammary epithelial cells in development and oncogenesis. The crosstalk between estrogen and
activin
that regulates
activin
ligand expression,
activin
and estrogen signal transduction, and cell cycle arrest was investigated in this study. Estrogen antagonized
activin
-dependent production of plasminogen activator inhibitor 1 (PAI-1) mRNA, while
activin
repressed estrogen-dependent transcription of
trefoil factor 1
. The repression of estrogen signaling by
activin
was recapitulated using a simple estrogen response element-luciferase construct and was enhanced in the presence of overexpressed estrogen receptor alpha (ERalpha). In contrast, estrogen-mediated repression of
activin
signaling could not be recapitulated on a simple CAGA Smad-binding element but did inhibit the short PAI-1 promoter, p3TP-luciferase, especially when ERalpha was overexpressed. Repression of both estrogen- and
activin
-regulated transcription was found to be ligand induced and Smad3 dependent. In addition to transcriptional repression, estrogen also reduced the amount of
activin
B mRNA and protein produced by MCF7 breast cancer cells. These studies demonstrate the importance of
activin
and estrogen crosstalk during mammary cell growth and cancer initiation.
...
PMID:Activin and estrogen crosstalk regulates transcription in human breast cancer cells. 1791 98
We previously showed that antral gastric tumors develop in gastrin-deficient (Gas(-/-)) mice. Therefore Gas(-/-) mice were studied sequentially over 12 months to identify molecular mechanisms underlying gastric transformation. Fundic atrophy developed by 9 months in Gas(-/-) mice. Antral mucosal hyperplasia developed coincident with the focal loss of
TFF1
and Muc5AC. Microarray analysis of 12 month Gas(-/-) tumors revealed an increase in follistatin, an
activin
/BMP antagonist. We found that elevated follistatin expression occurred in the proliferative neck zone of hyperplastic antrums, in antral tumors of Gas(-/-) mice, and also in human gastric cancers. Follistatin induced cyclin D1 and the trefoil factors
TFF1
and TFF2 in a gastric cancer cell line. We concluded that antral hyperplasia in Gas(-/-) mice involves amplification of mucous cell lineages due to follistatin, suggesting its role in the development of antral gastric tumors.
...
PMID:Induction of follistatin precedes gastric transformation in gastrin deficient mice. 1880 92